The evaluation of no-reflow and long-term efficacy of AMI with Tongxinluo

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-08000206

Enrollment

Unknown

Registered

2008-12-01

Start date

2007-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease, acute myocardial infarction

Interventions

Tongxinluo group:The Patients take Tongxinluo 2.08g together with Aspirin and Clopidogrel before emergency interventional treatment. After surgery, the Patients take 1.04g, t.i.d, Continuing 6 months

Placebo group:The Patients take Tongxinluo 2.08g together with Aspirin and Clopidogrel before emergency interventional treatment. After surgery, the Patients take 1.04g, t.i.d, Continuing 6 months aft

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 3. The onset of infarction chest pain within 12 hours; 4. ST paragraph in two or more limbs elevated lead >=0. lmv, ST paragraph in the chest by two or more elevated lead >=0.2mv; 5. Killip classification is a grade I-III; 6. Willing to accept the emergency intervention examination.

Exclusion criteria

Exclusion criteria: 1. There is a clear history of old myocardial infarction; 2. Having accepted emergency thrombolytic therapy; 3. The person who has long time (more than 20 minutes) Cardiopulmonary resuscitation; 4. Having clear mechanical complications, cardiogenic shock or difficult controlled the malignant arrhythmia; 5. Serious liver and kidney dysfunction; 6. Having gastrointestinal and Genitourinary System bleeding in four weeks; 7. At present, there has any active bleeding or known bleeding physical (including menstrual period); 8. Having serious bleeding and coagulation dysfunction, or using treatment doses of anticoagulant drugs (such as warfarin); 9. Having allergy or allergy to the research medicines; 10. Pregnancy or breast-feeding women; 11. The patients join the other clinical studies before the One month of incidence; 12. The persons have suspicious aortic; 13. The Other disease having clinical significance respiratory, digestive, blood, infection, Immunization, endocrine, neurological, tumours.

Design outcomes

Primary

Measure	Time frame
Coronary angiography;Isotope myocardial perfusion imaging;ECG;	—

Secondary

Measure	Time frame
Serum;Cardiac ultrasound examination and image analysis;	—

Countries

China

Contacts

Public ContactYang Yuejin

yangyjfw@yahoo.com.cn+86 010 88398080

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026